The FDA has recently approved an innovative blood test developed by Roche and Eli Lilly, which allows for the detection of biological signs of Alzheimer’s disease in individuals over 55 years old who are experiencing cognitive impairment. This method, less invasive than current examinations, assesses phosphorylated tau protein 217, a key biomarker. Although promising, the test should be used in conjunction with other medical evaluations for an accurate diagnosis.